Dipyridamole (Persantine)

Subscribe to Selected New Research on Dipyridamole

2651 relevant articles (171 outcomes, 499 trials/studies) found for this Drug

Description: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)

Also Known As:

Persantine; Miosen; Antistenocardin; Apo-Dipyridamole; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cerebrovase; Cléridium; Curantil; Curantyl; Dipyramidole; IPRAD Brand of Dipyridamole; Kurantil; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Persantin; Berlin Chemie Brand of Dipyridamole; Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 25

1-Ring Heterocyclic Compounds

2,6-bis(bis-(2-chloroethyl)amino)-4,8-dipiperidino-pyrimido(5,4-d)pyrimidine

bis(dipyridamole) tetrachloroplatinate(II)dipyridamole dihydrate

dipyridamole monoacetate

R-E 244

Experts

1.	Picano, Eugenio: 10 articles (01/2008 - 04/2002)
2.	Picano, E: 7 articles (12/2003 - 01/2000)
3.	De Schryver, E L L M: 5 articles (01/2007 - 01/2003)
4.	Diener, Hans-Christoph: 4 articles (09/2008 - 01/2005)
5.	van Gijn, J: 4 articles (01/2007 - 01/2003)
6.	Algra, A: 4 articles (01/2007 - 01/2003)
7.	Hiraki, Tatsuro: 3 articles (01/2008 - 06/2005)
8.	Zhao, Lian: 3 articles (01/2008 - 03/2005)
9.	Imaizumi, Tsutomu: 3 articles (01/2008 - 06/2005)
10.	Matsumoto, Manabu: 3 articles (01/2008 - 06/2005)

Related Diseases

1.	Stroke (Strokes) 09/15/1998 - "The sustained release dipyridamole produced a significant risk reduction of 16% for stroke, 15% for stroke and/or death but no significant reduction of mortality. " 07/01/2008 - "Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition. " 07/01/2008 - "OBJECTIVE: The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention. " 07/01/2008 - "CONCLUSION: Based on the results from these 2 large, randomized trials, ASA + dipyridamole was more effective than ASA monotherapy as first-line therapy for secondary stroke prevention in these patients with a history of minor stroke or TIA of noncardioembolic etiology." 06/01/2008 - "Two large clinical trials have established the superiority of the combination of ASA and extended-release dipyridamole (ASA/ERDP) over ASA alone in patients with recent noncardioembolic ischemic stroke or TIA. " Order ALL the reference details at left...
2.	Myocardial Infarction 12/01/1993 - "Dipyridamole echocardiography was well tolerated by elderly patients and proved to be very effective in prognostic stratification early after uncomplicated acute myocardial infarction, even when only survival was considered." 09/01/1997 - "CONCLUSIONS: Echocardiographic imaging during dipyridamole infusion is superior to sestamibi scintigraphy for predicting events after uncomplicated myocardial infarction." 03/01/1990 - "We have not found dipyridamole to be effective in the dog with coronary artery constriction and find no substantial evidence that it is effective in preventing myocardial infarction in man. " 07/01/1998 - "The aim of our study was to compare the prognostic information obtained early after an acute uncomplicated myocardial infarction of high dose dipyridamole coupled with echocardiography (stress echo) or maximal symptom-limited exercise testing. " 09/01/1997 - "The aim of our study was to compare the prognostic information obtained early after an acute uncomplicated myocardial infarction through high-dose dipyridamole coupled with echocardiography or scintigraphy via Tc 99m sestamibi SPECT imaging. " Order ALL the reference details at left...
3.	Coronary Artery Disease (Coronary Atherosclerosis) 10/01/1995 - "In patients with chronic coronary artery disease and a low incidence of cardiac events, dipyridamole echocardiography was effective in prognostic stratification, and positive low work load exercise ECG results were a reliable predictor of subsequent events. " 07/15/1992 - "Intravenous dipyridamole planar thallium-201 imaging is a safe and effective test for detection and prognosis of coronary artery disease (CAD) in the general population. " 03/01/1997 - "Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease." 02/01/1992 - "To evaluate the efficacy of stress technetium-99m MMI (N-2-methoxy-2-methyl propyl isonitrile) myocardial perfusion scintigraphy (Tc-99m MMI) using intravenous dipyridamole for detection of coronary artery disease (CAD), we collected 66 cases (53 men, 13 women, aged 40-79 years old) between Sept. " 02/01/1988 - "Thus, dipyridamole cardiac imaging is helpful in the diagnosis of coronary artery disease and in risk stratification." Order ALL the reference details at left...
4.	Myocardial Ischemia (Ischemic Heart Diseases) 03/01/1991 - "Thus, evaluation of early washout ratios (WR-25) after dipyridamole injection is a valuable method to increase sensitivity in assessing regional myocardial perfusion abnormality and is helpful in detection of ischemic heart disease, even with multivessel disease." 08/01/2001 - "Dipyridamole nuclear myocardial perfusion test is a safe and effective alternative to exercise nuclear perfusion testing for detecting myocardial ischemia. " 01/01/1996 - "In response to dipyridamole introduction improved myocardial perfusion was registered in 4 out of 6 patients, 1 patient showed signs of transient myocardial ischemia, 1 patient had stable defects of myocardial blood supply. " 07/01/2002 - "Study aim was the prospective assessment of the impact of dipyridamole-induced myocardial ischemia on the signal-averaged ECG. " 06/15/1994 - "Accordingly, the purpose of this study was to determine if reversible TI-201 defects in response to dipyridamole infusion are reflective of myocardial ischemia or secondary to regional differences in flow reserve. " Order ALL the reference details at left...
5.	Ischemia 03/01/1997 - "RESULTS: Results for sensitivity (89%) and negative predictive value (83%) in group 3 were significantly better than those in group 2 (71% [p = 0.03] and 56% [p = 0.002], respectively) and not significantly different from those in group 1. The polar maps of 20 patients studied with an without dipyridamole at the same exercise level revealed a significantly greater extent of ischemia in each territory and in a global assessment (19 + 20% vs. 8 + 11%, p < 0.0001) when dipyridamole was administered during physical exercise. " 08/01/1989 - "The increase in rate-pressure product (RPP = mm Hg x beats/min x 100) measured during the exercise stress test in the patients in group I was significantly greater than that determined during dipyridamole-induced ischemia (204 +/- 41 versus 145 +/- 33, p less than 0.01). " 06/01/1983 - "Rapid atrial pacing performed before and at 60, 90, and 120 minutes after dipyridamole failed to demonstrate any significant reduction in pacing threshold or evidence of increased ischemia after dipyridamole. " 09/15/1993 - "This study evaluates dipyridamole stress echocardiography in silent ischemia. " 09/01/1992 - "Dipyridamole given before the 30-minute ischemia, without preconditioning, did not reduce %IS/AR (55.3 +/- 5.2%, n = 7), and a previous study from this laboratory had demonstrated that the present dose of 8-PT alone did not modify IS in the rabbit. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	clopidogrel (Plavix)
3.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
4.	Thallium
5.	Adenosine
6.	Ticlopidine (Ticlid)
7.	Dobutamine
8.	Prednisolone (Predate)
9.	Dipyridamole (Persantine)
10.	Warfarin (Coumadin)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Plasma Exchange
4.	Prostheses and Implants (Prosthesis)
5.	Angioplasty (Angioplasties)

Best Treatments:
Research Summary Report
on Stroke

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2274 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>